AL amyloidosis
From Wikipedia, the free encyclopedia
| AL amyloidosis Classification and external resources |
|
| ICD-10 | E85. |
|---|---|
| ICD-9 | 277.3 |
| OMIM | 254500 |
| DiseasesDB | 315 |
| eMedicine | med/3363 |
AL amyloidosis is the most common form of systemic amyloidosis in the US.[1]
It occurs in 5 to 15% of people with multiple myeloma.[citation needed]
The "AL" refers to antibody light chain.[2]
[edit] Presentation
The Bence Jones proteins produced are necessary to produce amyloidosis but other factors are required for amyloidosis to occur. Most people with AL amyloidosis do not have multiple myeloma, or any other B cell tumour. They often have a serum gammopathy, and it is unknown whether these cases will ultimately evolve into myeloma, as these people often die from their amyloidosis before malignant transformation occurs.
[edit] Treatment
Treatment can involve application of chemotherapy similar to that used in multiple myeloma.[3]
A combination of bortezomib and dexamethasone has been proposed,[4] as has melphalan and dexamethasone.[5]
[edit] References
- ^ Gertz MA (June 2004). "The classification and typing of amyloid deposits". Am. J. Clin. Pathol. 121 (6): 787–9. doi:. PMID 15198347.
- ^ Amyloidosis Causes, Diagnosis, Symptoms, and Treatment on MedicineNet.com.
- ^ BU.
- ^ Kastritis E, Anagnostopoulos A, Roussou M, et al (October 2007). "Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone". Haematologica 92 (10): 1351–8. doi:. PMID 18024372.
- ^ Palladini G, Perfetti V, Obici L, et al (April 2004). "Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation". Blood 103 (8): 2936–8. doi:. PMID 15070667.
|
|||||||||||
